AUGVESTA

Serial Number 97260157
602

Registration Progress

Application Filed
Feb 9, 2022
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

AUGVESTA

Basic Information

Serial Number
97260157
Filing Date
February 9, 2022
Abandonment Date
April 25, 2023
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
May 8, 2023
Classes
005

Rights Holder

Pfizer Inc.

03
Address
235 East 42nd Street
New York, NY 10017

Ownership History

Pfizer Inc.

Original Applicant
03
New York, NY

Legal Representation

Attorney
Andrea Christensen

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

9 events
Date Code Type Description Documents
May 8, 2023 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
May 8, 2023 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Loading...
May 8, 2023 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Oct 24, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 24, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Oct 24, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 20, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 15, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 12, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for the treatment of muscular dystrophy
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005